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he Only Better Alternative
o Rescue Percutaneous
oronary Intervention Is
rimary Percutaneous
oronary Intervention*
jin Ndrepepa, MD, Albert Schömig, MD,
dnan Kastrati, MD
unich, Germany
he superiority of primary percutaneous coronary interven-
ion (PCI) over thrombolysis as a reperfusion strategy in
atients with ST-segment elevation myocardial infarction
STEMI) has been sufficiently documented (1). However,
hrombolysis still remains a frequently used therapeutic
ption for patients with STEMI, for the most part due to
onstraints in offering PCI in a timely manner (2,3). Even
ith the use of advanced fibrin-specific thrombolytic agents,
hrombolysis restores normal epicardial blood flow—
hrombolysis In Myocardial Infarction (TIMI) flow grade 3
See page 118
in only slightly more than one-half of patients with
TEMI (4). The efficacy of thrombolysis is highly time-
ependent, with drastic attenuation in benefit if the interval
rom onset of symptoms exceeds 6 h (5). Available evidence
hows that patients with an occluded infarct-related artery
TIMI flow grade 0 to 1) and those with suboptimal blood
ow restoration (TIMI flow grade 2) have increased mor-
ality compared with patients with complete restoration of
nterograde flow (TIMI flow grade 3) (6). It has recently
een estimated that nearly 125,000 patients with STEMI
ill have suboptimal reperfusion with thrombolytic therapy
n the U.S. per annum (7). Despite the frequent occurrence
nd clinical impact, the therapeutic options for patients with
ailed thrombolysis continue to be a much debated issue.
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From Deutsches Herzzentrum, Technische Universität, Munich, Germany. Dr.i
astrati received lecture fees from Bristol-Myers Squibb, Biotronik, Cordis, Eli Lilly
Co., The Medicines Company, Medtronic, and Sanofi-Aventis.Over the years, the concept of rescue PCI as a treatment
or failed thrombolysis has evolved from a “conscience
ranquilizer” to a valuable therapeutic option with the
apacity to improve the health of patients (8). The efficacy
f rescue PCI has been investigated in the settings of large
hrombolytic trials, trials of systematic and facilitated PCI,
rials of transfer for primary PCI, and randomized trials
pecifically designed to investigate rescue PCI. In the last 5
ears, 2 trials of rescue PCI for failed thrombolysis have been
ublished: the MERLIN (Middlesbrough Early Revasculari-
ation to Limit Infarction) trial (9) and the REACT (Rescue
ngioplasty Versus Conservative Treatment or Repeat
hrombolysis) trial (10). Although these trials came to oppo-
ite conclusions with regard to the efficacy of rescue PCI,
ostly due to substantial differences in their design and the risk
f patients included, they are instrumental to the understand-
ng of the place of rescue PCI in the treatment of STEMI
atients with failed thrombolysis, and to some extent, they
eflect the contemporary practice of interventional cardiology.
In this issue of the Journal, Carver et al. (11) report on the
ong-term results of the REACT trial. Briefly, the REACT
rial included 427 patients, 21 to 85 years of age, with
TEMI within 6 h of symptom onset and 90-min electro-
ardiographic criteria (50% ST-segment resolution in the
ead with previous maximal ST-segment elevation) for
ailed thrombolysis. Patients were randomly assigned to
escue PCI (n  144), repeat thrombolysis (n  142), or
onservative therapy (n  141). Due to problems with the
ecruitment of patients and funding, the trial was prema-
urely terminated. In the present article, the authors report
n the primary composite end point of death, recurrent
yocardial infarction, cerebrovascular events, and severe
eart failure at 1 year, and mortality at a median of 4.4 years.
rom 6 months to 1 year, there were few events in each of
he study arms, so that the 6-month advantage in event-free
urvival was maintained at 1 year of follow-up (81.5%,
7.5%, and 64.1% in rescue PCI, conservative therapy, and
epeat thrombolysis arms, respectively; p 0.004). Of note,
he most important finding of this study was a significant
eduction in long-term mortality: 11.2% for rescue PCI,
2.4% for conservative therapy, and 22.3% for repeat
hrombolysis. Also, of importance but not unexpected was
he finding that repeat thrombolysis did not offer any benefit
ompared with conservative therapy (11).
Almost all prior rescue PCI trials used an outdated PCI
echnology and adjunctive antithrombotic therapy and
herefore are not reflective of current practice. With coro-
ary stent use in 68.5% of patients and glycoprotein IIb/IIIa
eceptor blocker (abciximab) administration in 43.4% of
atients, the REACT trial better reflects the contemporary
ractice of interventional cardiology. In a randomized trial
f rescue stenting versus rescue balloon angioplasty, both
ith the adjunct use of abciximab, Schömig et al. (12)
howed that the use of stents was associated with a signif-
cantly greater myocardial salvage compared with angio-
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Rescue and Primary PCI July 7, 2009:127–9lasty alone. Moreover, glycoprotein IIb/IIIa receptor
lockers may reduce the excessive risk of thrombus forma-
ion seen after failed lytic therapy, which is consequent on
ost-thrombolytic platelet activation (13). These factors
ould be instrumental to the understanding of the superior
esults of rescue PCI in the REACT trial.
Several aspects of rescue PCI for failed thrombolysis need
urther clarification in future studies. A loading dose of
hienopyridines (clopidogrel and more recently prasugrel)—a
tandard adjunct of current periprocedural antithrombotic
herapy during PCI—has not been investigated in the setting
f rescue PCI. The role of thrombus aspiration also needs to be
valuated in the setting of rescue PCI. Although the new
trategies including drug-eluting stents certainly deserve to
ecome the focus of future studies on rescue PCI, for the time
eing, the REACT trial remains the most mature, contempo-
ary, and important trial on the management of patients with
ailed thrombolysis.
The most recent guidelines of the Task Forces of the
merican College of Cardiology/American Heart Associa-
ion (2) and the European Society of Cardiology (3) assign
Class IIA recommendation to rescue PCI. This is because
ot all randomized trials on rescue PCI were able to show
uch a clear advantage from this form of therapy as did the
EACT trial. We performed a meta-analysis using data on
ortality at the longest available follow-up obtained from
he most recent updated reports on 6 existing trials: the trial
f Belenkie et al. (14), the MERLIN trial (15), the REACT
rial (11), the RESCUE (Randomized Comparison of
escue Angioplasty With Conservative Management of
Figure 1 Risk of Death in 6 Randomized Trials Comparing Resc
The source of the trials is found in the text. FU  follow-up; PCI  percutaneous catients With Early Failure of Thrombolysis for Acute tnterior Myocardial Infarction) 1 and 2 trials (16), as well
s the TAMI (Thrombolysis and Angioplasty in Myocardial
nfarction) trial (16). As shown in Figure 1, in the pooled
ample of 908 patients, there was a nonsignificant, slightly
ore than 25% risk reduction in 1- to 4-year mortality from
escue PCI. This is enough to recommend rescue PCI as the
est option after failed thrombolysis, yet none of the trials
nd even the pooled population provided sufficient power to
ssess mortality. The failure to enroll more patients in
andomized trials on rescue PCI in the past, when throm-
olysis was the dominant reperfusion treatment of patients
ith STEMI, makes the realization of larger trials in the
uture unlikely. The use of thrombolysis as a reperfusion
trategy in patients with STEMI has markedly decreased.
s recently reported in GRACE (Global Registry of Acute
oronary Events), which included 10,954 patients with
TEMI presenting within 12 h of symptom onset, the use
f primary PCI increased from 15% to 44%, and the use of
hrombolysis decreased from 41% to 16% over the period
etween April 1999 and June 2006 (17). Although these
rends reduce the chances of having large studies conducted
n rescue PCI, they strengthen the hope that rescue PCI
ill be needed increasingly less in the future. The recent
tory of thrombolysis is far from being a success story. In
atients with STEMI, thrombolysis was proven to be
nferior to PCI as stand-alone therapy (1) and even harmful
f used in an effort to “facilitate” subsequent PCI (18). With
his in mind, the only better alternative to rescue PCI is
rimary PCI. Until this concept is universally accepted and
pplied, PCI after failed thrombolysis will indeed continue
CI With Conservative Treatment After Failed Thrombolysis
ry intervention.ue P
oronao save patients’ lives. However, the survival of thrombolysis
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July 7, 2009:127–9 Rescue and Primary PCIs a treatment strategy in STEMI may largely be dependent
n the effectiveness of rescue PCI.
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